医药魔方 / 最新资讯 / 正文

重磅!礼来80亿美元收购明星公司Loxo,补强肿瘤管线

医药魔方 医药魔方 来源:医药魔方
2019-01-08
礼来
原文

1月7日,礼来宣布将以235美元/股的价格全现金收购Loxo Oncology公司,交易总额80亿美元。双方此项交易计划在2019Q1完成。



Loxo Oncology 公司管线中有一系列颇具市场潜力的药物,包括:


LOXO-292,First in class的RET抑制剂,已被FDA授予针对3种适应症的突破性疗法资格,有望在2020年首次获批。RET融合和突变发生在多种肿瘤类型中,包括肺癌、甲状腺癌以及其他一些肿瘤类型中(新一代明星RET抑制剂的头对头较量:BLU-667 vs LOXO-292)。


LOXO-305,口服BTK抑制剂,目前处于I/II期阶段。


Vitrakvi, first-in-class的口服TRK抑制剂,由Loxo和拜耳共同开发,刚刚获得FDA批准,是Keytruda之后第2款基于肿瘤分子标记物而不区分肿瘤类型的肿瘤药。


LOXO-195,TRK抑制剂,由LOXO和拜耳共同开发,用于对TRK抑制剂获得性耐药的患者,有望在2022年获批。


机器翻译

On January 7, Eli Lilly announced that it will acquire Loxo Oncology for $235 per share in full cash, totaling $8 billion.The deal is scheduled to be completed in 2019Q1.

zzzzz.

Loxo Oncology has a range of drugs with considerable market potential in its pipeline, including:

LOXO-292, a RET inhibitor of First in Class, which has been granted FDA qualification for breakthrough therapies for three indications and is expected to be approved for the first time in 2020.RET fusions and mutations occur in a variety of tumor types, including lung cancer, thyroid cancer, and some other tumor types (head-to-head competition for new generation star RET inhibitors: BLU-667 vs LOXO-292).

LOXO-305, an oral BTK inhibitor, is currently in Phase I/II.

Vitrakvi, an oral TRK inhibitor of the first-in-class, developed jointly by Loxo and Bayer and just approved by the FDA, is Keytruda's second oncology drug based on tumor molecular markers without distinguishing between tumor types.

LOXO-195, a TRK inhibitor, developed jointly by LOXO and Bayer for patients with acquired resistance to TRK inhibitors, is expected to be approved in 2022.

扫码实时看更多精彩文章

版权及免责声明 本文由医药魔方原创,版权归医药魔方所有。未经许可,严禁任何媒体或个人以任何形式摘编、改写、复制、转载本文内容。对于恶意侵权行为,医药魔方保留采用法律手段追究的权利。媒体内容及商务合作请联系医药魔方工作人员(微信号:medicube)

魔方微信公众号